ASH 2018 | Characterization of the immune impact of daratumumab by mass cytometry in multiple myeloma
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Immune alterations in multiple myeloma (MM) involve several cell types, and so mass cytometry can be utilized to study a diverse set of single cells simultaneously. Here, Gareth Morgan, MD, PhD, FRCP, FRCPath, of the UAMS Myeloma Institute, Little Rock, AR, discusses the immune system profiling of MM using CyTOF mass spectrometry, the new platform that couples mass spectrometry with single-cell flow cytometry, allowing the observation of significant changes to the immune status post-daratumumab (DARA) treatment.
Get great new content delivered to your inboxSign up